Luk JM - Search Results

1

Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.

Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, Feng T, Zhu L, Rong Y, Shen H, Luk JM, Zhang X, Qin N. Zhou Z, et al. Among authors: luk jm. FASEB J. 2015 Feb;29(2):724-32. doi: 10.1096/fj.14-262980. Epub 2014 Nov 10. FASEB J. 2015. PMID: 25384421

2

An update on targeting Hippo-YAP signaling in liver cancer.

Liu AM, Xu Z, Luk JM. Liu AM, et al. Among authors: luk jm. Expert Opin Ther Targets. 2012 Mar;16(3):243-7. doi: 10.1517/14728222.2012.662958. Epub 2012 Feb 16. Expert Opin Ther Targets. 2012. PMID: 22335485

3

Targeting YAP and Hippo signaling pathway in liver cancer.

Liu AM, Xu MZ, Chen J, Poon RT, Luk JM. Liu AM, et al. Among authors: luk jm. Expert Opin Ther Targets. 2010 Aug;14(8):855-68. doi: 10.1517/14728222.2010.499361. Expert Opin Ther Targets. 2010. PMID: 20545481 Review.

4

Characterization of two novel LPS-binding sites in leukocyte integrin betaA domain.

Wong KF, Luk JM, Cheng RH, Klickstein LB, Fan ST. Wong KF, et al. Among authors: luk jm. FASEB J. 2007 Oct;21(12):3231-9. doi: 10.1096/fj.06-7579com. Epub 2007 May 23. FASEB J. 2007. PMID: 17522381

5

AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.

Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W, Luk JM. Xu MZ, et al. Among authors: luk jm. Oncogene. 2011 Mar 10;30(10):1229-40. doi: 10.1038/onc.2010.504. Epub 2010 Nov 15. Oncogene. 2011. PMID: 21076472 Free PMC article.

6

Regulators of mammalian Hippo pathway in cancer.

Liu AM, Wong KF, Jiang X, Qiao Y, Luk JM. Liu AM, et al. Among authors: luk jm. Biochim Biophys Acta. 2012 Dec;1826(2):357-64. doi: 10.1016/j.bbcan.2012.05.006. Epub 2012 Jun 7. Biochim Biophys Acta. 2012. PMID: 22683405 Review.

7

Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma.

Huo X, Zhang Q, Liu AM, Tang C, Gong Y, Bian J, Luk JM, Xu Z, Chen J. Huo X, et al. Among authors: luk jm. Oncol Rep. 2013 Feb;29(2):840-6. doi: 10.3892/or.2012.2176. Epub 2012 Dec 10. Oncol Rep. 2013. PMID: 23232767

8

MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties.

Liu AM, Poon RT, Luk JM. Liu AM, et al. Among authors: luk jm. Biochem Biophys Res Commun. 2010 Apr 9;394(3):623-7. doi: 10.1016/j.bbrc.2010.03.036. Epub 2010 Mar 10. Biochem Biophys Res Commun. 2010. PMID: 20226166

9

The use of small peptides in the diagnosis and treatment of hepatocellular carcinoma.

Tsang FH, Lee NP, Luk JM. Tsang FH, et al. Among authors: luk jm. Protein Pept Lett. 2009;16(5):530-8. doi: 10.2174/092986609788167860. Protein Pept Lett. 2009. PMID: 19442232 Review.

10

Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.

Wong KF, Liu AM, Hong W, Xu Z, Luk JM. Wong KF, et al. Among authors: luk jm. Oncotarget. 2016 Nov 22;7(47):77683-77695. doi: 10.18632/oncotarget.12760. Oncotarget. 2016. PMID: 27765911 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

189 results

Search Page